T/CAMDI 122-2023 Active Group standards

General requirements for 3D bioprinted tumor models according to T/CAMDI 122-2023

T/CAMDI 122-2023

Publish Date: 2023-12-28 Implement Date: 2023-12-31 For services related to genuine standard inquiry, procurement, translation, and other related services in China, please Contact Us

Price: $ 20.00

Download

Basic Information

Standard Code: T/CAMDI 122-2023

Standard Type: Group standards

Standard Status: Active

is_force_gb: no

CCS Name: -

ICS Name: Surgical implants, prostheses, and orthoses

Publish Date: 2023-12-28

Implement Date: 2023-12-31

Pages: 9 pages

Scope

Main technical content: This document specifies the general requirements for 3D bioprinted tumor models. This document is applicable to tumor models constructed based on 3D bioprinting, which are used in basic research on tumors, diagnosis of tumor molecular subtypes, and sensitivity testing of anti-tumor drugs. Drug sensitivity testing may include, but is not limited to, chemotherapy drugs, targeted drugs, immunotherapy drugs, and candidate compounds for new drugs; it can test a single drug or a combination of drugs.